Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 3/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19637212 | 0.84 | CYP4F2 (0.44) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL22527541 | 0.83 | RXRA (0.40) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL24968167 | 0.82 | RXRA (0.42) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL21196032 | 0.81 | CYP4F2 (0.44) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL21198168 | 0.81 | ALDH1A1 (0.45) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30758927 | 0.81 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25426460 | 0.81 | RXRA (0.46) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL19949097 | 0.81 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29478977 | 0.81 | CYP4F2 (0.44) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL19617703 | 0.81 | RXRA (0.41) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | RXRA 2707/4885RXRB 2175/4885RXRG 1709/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RXRA 3298/4885RXRB 2693/4885RXRG 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.